Background
Hypertrophic obstructive cardiomyopathy (HOCM) is mainly characterized by left ventricular outflow tract (LVOT) obstruction due to unexplained myocardial hypertrophy and septal reduction therapies are considered the preferred treatments for HOCM patients with drug-refractory symptom [
1,
2]. Most patients benefited from the amelioration of LVOT obstruction and the improvement of myocardial contractile function in the follow-up period [
3‐
5]. As an innovative procedure for the treatment of HOCM, PIMSRA has been clinically performed for several years and several studies have confirmed its safety and effectiveness in the majority of cases [
3,
4]. In a small number of cases, whereas, the occurrence of postoperative hypotension (POH), which could aggravate severe LVOT obstruction and consequent low cardiac output, remains a challenging complication during perioperative management. In addition, plenty of studies authenticate that POH is associated with an increased risk of long-term prognosis [
6]. Therefore, ascertaining the risk factors of POH and preoperatively identifying patients with a high risk of POH is of great significance for optimizing the management of PIMSRA.
Studies found that some indicators reflecting patients’ demographic, hemodynamic, and metabolic profiles may predict the risk of postoperative hypotension, and hypotension can be subcategorized as cardiogenic or hypovolemic in most cases [
7,
8]. The estimated plasma volume status (ePVS) estimated by the Duarte formula which assesses the volume overload and reflects the prognosis at a very low cost, has proven to be associated with clinical outcomes in patients with heart failure (HF) [
9‐
11]. Several reports assessed the correlation between ePVS and actual plasma volume measured using conventional radioisotope-labeled albumin or red blood cell assays and found that the ePVS derived from the formulas and actual plasma volume using the gold standard method showed a moderate-to-strong correlation [
12‐
14]. To date, no researchers have evaluated ePVS and analyzed its association with prognosis in hypertrophic cardiomyopathy.
This study intended to analyze the ePVS in patients with hypertrophic cardiomyopathy and analyze whether it is related to postoperative hypotension after PIMSRA treatment.
Discussion
In this study, we investigated the prevalence of POH and the ePVS in 405 patients with severely symptomatic HOCM who underwent PIMSRA. In this study, results showed that there were 53 (13.1%) patients suffering from POH. The ePVS, which was higher in patients with POH, demonstrated association with the POH. For every 1-unit increase in ePVS, the patient's risk of POH increased by more than 50%, after adjusting for the effects of other confounders. To best of our knowledge, this was the first study that evaluate the ePVS in HOCM patients and investigated its association with POH.
Hypotension and related complications after cardiovascular intervention were common and deleterious, which can cause syncope or shock, leading to irreversible organ damage and even threaten the lives of patients in severe cases [
16]. In patients with HOCM, hypotension can lead to exacerbation of LVOT and SAM, which is a key pathophysiological mechanism leading to hemodynamic instability [
19,
20]. The timely detection and treatment of POH after PIMSRA is crucial for patients to stably pass through the perioperative period.
The Duarte ePVS provides a method that instantaneously estimate the plasma status [
9]. In the largest study to date (data from the NHANS database, involving 42705 participants from 1999-2014), the mean ePVS in the general population was 4.2 ± 0.84 mL/g [
10]. Another study recruited 1747 patients diagnosed with HF with preserved ejection fraction and found that the mean ePVS was 4.9 ± 1.0 mL/g [
21]. Our research found that ePVS in all HOCM patients was lower compared to that in the general population or patients with heart failure, consistent with the view that HOCM is characterized by reduced intravascular volume and elevated BNP induced by high intracavity pressure in HOCM.
The ePVS was found lower in HOCM patients, but in this cohort the patients observed with POH demonstrated higher ePVS compared with patients without POH. This association may be explained by the relationship between ePVS and cardiovascular function. HOCM patients may develop HF symptoms with progression of disease. The ePVS, an indicator originally designed to quantitatively evaluate congestion in patients with heart failure, is elevated when the HF and fluid retention had developed [
22]. Higher ePVS in patients with POH suggested that these patients may have preoperatively suffered from more severe HF and intravascular congestion, leading to lower cardiac reserve and susceptibility to POH, although higher ePVS suggested more sufficient intravascular volume.
Up to now, the ePVS has not been established as a recognized normal range or diagnostic criteria due to the differences of the research population. In particular, there is no large sample study evaluating ePVS in the HCM population. In this study, we found that the median of ePVS in HOCM patients with POH was much higher than that in HOCM patients without POH. The significant difference of ePVS suggested that this index may have some potential and reasonable sensitivity to predict at risk patients for POH.
We performed sensitivity analysis using the Hakim-Kaplan ePVS instead of the Duarte ePVS and found that the two clusters of ePVS were robustly associated with the risk of POH and that both methods might be worthwhile to evaluate the risk of POH in HOCM patients. It's worth noting that the Hakim-Kaplan formula to obtain ePVS requires the dry weight which is often not assessed in patients with cardiovascular diseases. There were some researches suggesting Hakim-Kaplan ePVS calculated from general body weight may also have an association with in-hospital and post-discharge outcomes in decompensated heart failure [
4].
This study didn’t exclude the patients who postoperatively received targeted blood pressure management. The ePVS was susceptible to fluid infusion and the postoperative application of fluid infusion and vasopressors may account for the limited predictive performance of ePVS. We hypothesized that changes in ePVS during postoperative management could further add to the prognostic value of ePVS. The perioperative management experience of surgeries including septal reduction therapies suggested that HCM patients may have insufficient cardiac output and need to be monitored during the fluid infusion process to prevent pulmonary edema [
23,
24]. Therefore, it is imperative to evaluate the volume status of patients by the ePVS for the perioperative management of patients with hypertrophic cardiomyopathy. Prospective research following a standardized blood sample-collecting method is needed to confirm the application value of ePVS.
This study has several limitations. Firstly, it is based on the retrospective analysis of registry trials and has the inherent limits of a retrospective study, that clinicians or investigators may not capture absolutely accurate information. Second, the sample of blood cell examination is not collected with strict rules, which may bring potential risks of bias. Thirdly, as mentioned before, the postoperative management within all HOCM patients who underwent PIMSRA have individual differences and this may cover the relationship between the ePVS and postoperative hypotension. Fourthly, the lack of routine blood tests during postoperative management precluded the comparison between postoperative ePVS and baseline and this may be an important issue for future research.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (
http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.